Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Lückerath, Katharina ^a   Lapa, Constantin ^a   Spahmann, Annika ^a   Jörg, Gerhard ^a   Samnick, Samuel ^a   Rosenwald, Andreas ^a   Einsele, Herrmann ^a   Knop, Stefan ^a   Buck, Andreas K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORODEOXYGLUCOSE F18; HUMANS; METHIONINE; MULTIPLE MYELOMA; PARAPROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; STATISTICS, NONPARAMETRIC; TYROSINE;

EID: 84893331128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084840     Document Type: Article

References (42)

1. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S et al. (2004) A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 127: 299-304. doi:10.1111/j.1365-2141.2004.05207.x. PubMed: 15491289. (Pubitemid 39468943)
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
3. Kuehl WM, Bergsagel PL (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 122: 3456-3463. doi:10.1172/JCI61188. PubMed: 23023717.
4. Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O et al. (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27: 473-481. doi:10.1038/leu.2012.226. PubMed: 22874878.
5. Morgan GJ, Kaiser MF (2012) How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2012: 342-349
6. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M et al. (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 23: 1545-1556. doi:10.1038/leu.2009.89. PubMed: 19421229.
7. Durie BG (2006) The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 42: 1539-1543. doi:10.1016/j.ejca.2005.11.037. PubMed: 16777405.
8. Durie BG, Waxman AD, D'Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43: 1457-1463. PubMed: 12411548. (Pubitemid 35285870)
9. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG et al. (2013) Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 162: 50-61. doi:10.1111/bjh.12346. PubMed: 23617231.
10. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr., van Rhee F et al. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114: 2068-2076. doi:10.1182/blood-2009-03-213280. PubMed: 19443657.
11. Terpos E, Moulopoulos LA, Dimopoulos MA (2011) Advances in imaging and the management of myeloma bone disease. J Clin Oncol 29: 1907-1915. doi:10.1200/JCO.2010.32.5449. PubMed: 21483016.
12. Burger R, Trautmann U, Hansen-Hagge TE, Strobel G, Bartram C, Kalden JR, Gramatzki M (1994) Two new interleukin-6 dependent plasma cell lines carrying a chromosomal abnormality involving the IL-6 gene locus. Br J Haematol 87: 4212.
13. Bourdier T, Greguric I, Roselt P, Jackson T, Faragalla J et al. (2011) Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FX(FN) module. Nucl Med Biol 38: 645-651. doi:10.1016/j.nucmedbio. 2011.01.001. PubMed: 21718939.
14. Kniess T, Rode K, Wuest F (2008) Practical experiences with the synthesis of [11C] CH3I through gas phase iodination reaction using a TRACERlabFXC synthesis module. Appl Radiat Isot 66: 482-488. (Pubitemid 351297737)
15. Gomzina NA, Kuznetsova OF (2011) L-[methyl-(11C)]-methionine of high enantiomeric purity production via on-line 11C-methylation of L-homocysteine thiolactone hydrochloride. Bioorg Khim 37: 216-222. PubMed: 21721254.
16. Hillengass J, Landgren O (2013) Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma". Leuk Lymphoma 54: 1355-1363. doi:10.3109/10428194.2012.740559. PubMed: 23289361.
17. Agarwal A, Chirindel A, Shah BA, Subramaniam RM (2013) Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol 200: 884-890. doi:10.2214/AJR.12.9653. PubMed: 23521465.
18. Bannas P, Kröger N, Adam G, Derlin T (2013) Modern imaging techniques in patients with multiple myeloma. Rofo 185: 26-33. PubMed: 23196838.
19. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF et al. (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49: 1928-1935. doi:10.2967/jnumed.108.056713. PubMed: 18997054.
20. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M (2003) Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 18: 841-845. doi:10.1089/108497803770418382. PubMed: 14629832. (Pubitemid 37377319)
21. Shortt CP, Gleeson TG, Breen KA, McHugh J, O'Connell MJ et al. (2009) Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 192: 980-986. doi:10.2214/AJR.08.1633. PubMed: 19304704.
22. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E et al. (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118: 5989-5995. doi:10.1182/blood-2011-06-361386. PubMed: 21900189.
23. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM et al. (2007) Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT - Initial Experience. Radiology 242: 498-508. doi:10.1148/radiol.2422051980. PubMed: 17179397. (Pubitemid 46146203)
24. Nakamoto Y, Kurihara K, Nishizawa M, Yamashita K, Nakatani K, et al. (2013) Clinical value of (1)(1)C-methionine PET/CT in patients with plasma cell malignancy: comparison with (1)(8)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 40: 708-715
25. Ishiwata K, Vaalburg W, Elsinga PH, Paans AM, Woldring MG (1988) Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med 29: 1419-1427. PubMed: 3261334.
26. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ et al. (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42: 432-445. PubMed: 11337520. (Pubitemid 32207394)
27. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H et al. (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23: 215-224. doi:10.1038/leu.2008.307. PubMed: 19020545.
28. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O et al. (2003) Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101: 4998-5006. doi:10.1182/blood-2002-11-3385. PubMed: 12623842. (Pubitemid 36857764)
29. Reijmers RM, Spaargaren M, Pals ST (2013) Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J 280: 2180-2193. doi:10.1111/febs.12180. PubMed: 23419151.
30. Iwama K, Chihara D, Tsuda K, Ugai T, Sugihara H et al. (2013) Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol 90: 134-141. doi:10.1111/ejh.12050. PubMed: 23210517.
31. Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J et al. (2013) Evaluation of intratumoural heterogeneity on (1)(8)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40: 685-692. doi:10.1007/s00259-012-2314-6. PubMed: 23232507.
32. Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C et al. (2013) BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 19: 357-366. doi:10.1158/1078-0432.CCR-12-2333. PubMed: 23213054.
33. Harris SM, Davis JC, Snyder SE, Butch ER, Vavere AL et al. (2013) Evaluation of the Biodistribution of 11C-Methionine in Children and Young Adults. J Nucl Med.
34. Delcommenne M, Klingemann HG (2012) Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments. Hum Antibodies 21: 29-40. PubMed: 22885958.
35. Rousseau C, Ferrer L, Supiot S, Bardiès M, Davodeau F et al. (2012) Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 33: 679-688. doi:10.1007/s13277-012-0362-y. PubMed: 22389160.
36. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351. doi:10.1182/blood-2008-10-186668. PubMed: 19139079.
37. Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S et al. (2009) Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 24: 1150-1161. doi:10.1359/jbmr.090210. PubMed: 19335218.
38. Kim HY, Hwang JY, Kim SW, Lee HJ, Yun HJ et al. (2010) The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro. Cancer Res Treat 42: 225-234. doi:10.4143/crt.2010.42.4.225. PubMed: 21253325.
39. Udi J, Schüler J, Wider D, Ihorst G, Catusse J et al. (2013) Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol 161: 104-116. doi:10.1111/bjh.12226. PubMed: 23384035.
40. Finno CJ, Famula T, Aleman M, Higgins RJ, Madigan JE et al. (2013) Pedigree analysis and exclusion of alpha-tocopherol transfer protein (TTPA) as a candidate gene for neuroaxonal dystrophy in the American Quarter Horse. J Vet Intern Med 27: 177-185. doi:10.1111/jvim.12015. PubMed: 23186252.
41. Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA et al. (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia.
42. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R et al. (2010) Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 99: 217-225. doi:10.1007/s11060-010-0117-9. PubMed: 20091333.